TheranosticTrials.org

Clinical Trial · NCT03489473

FESPET Study: Female EStrogen recePtor in Endometrial Cancer Treatment

Overview

Endometrial cancer is the most common gynecological malignancy in the western world and its incidence is expected to increase in the coming years due to obesity. Major treatment modalities include surgery, radiotherapy and chemotherapy. Hormonal therapy can be considered in primary treatment if other treatment modalities are not feasible and in treatment for recurrent disease. Hormonal treatment has shown to be more effective in endometrial cancers expressing estrogen (ER) and progesterone receptor (PR). Tumor heterogeneity frequently causes loss of expression of ER and PR in metastasis compared to primary tumors. The FES PET CT scan combines PET-CT scan with an estrogen tracer, thus allowing non invasive visualisation of estrogen receptor, even in patients with metastasis that are difficult to reach for biopsy. FES PET has been shown to relate well to ER expression and to treatment response in breast cancer. This study explores the feasibility of the FES PET scan in endometrial cancer patients.

Sponsor

Radboud University Medical Center

Contacts

JMA Pijnenborg, MD, PhD (PRINCIPAL_INVESTIGATOR)

Willem Jan van Weelden, MD (CONTACT)

willemjan.vanweelden@radboudumc.nl

0031643274577

ClinicalTrials.gov

NCT03489473

Drug / Compound

FES

Isotope(s):
Target(s):
  • Estrogen Receptor
Ligand Class: Small Molecules

Eligibility

Inclusion

  • Availability of recent (micro)curettage or biopsy
  • All histologic types of endometrial cancer (e.g. endometrioid, clear cell, serous subtype)
  • Postmenopausal status
  • Primary or metastatic endometrial cancer in which hormonal treatment is the planned treatment

Exclusion

  • Contra-indications to perform a PET-CT scan or a CT scan with intravenous contrast
  • Use of hormonal therapy in the three months preceding performance of FES PET
  • Intercurrent treatment between biopsy taking and start of hormonal treatment